Key words: protein phosphatase/protein phosphorylation/cytoskeleton/myosin light chain ABSTRACT. Effects of the protein phosphatase inhibitors, tautomycin and calyculin A on protein phosphorylation and cytoskeleton of human platelets. It has been discovered recently that manycytotoxic compoundsisolated from a variety of sources are potent phosphatase inhibitors. Two of these, tautomycin (TM) and calyculin-A (CL-A) were applied to human platelets to investigate the role of protein phosphorylation on cytoskeletal structure and function. Exposure to 10 pM TMor 0.1 pM CL-A induced marked morphological changes. The granules were centralized and surrounded by actin filaments, but there was no evidence of granule release. Myosin became more centralized, was occluded from the granulomere, but was not confined to the micro filament ring. These changes occurred without an increase in cytosolic Ca2+ concentrations, as determined by measurements with fura-2. TMand CL-Ainduced an overall increase in protein phosphorylation. Phosphorylation of the 20,000 dalton light chain of myosin increased markedly and multiple phosphorylation sites were indicated. Cytoskeletons were prepared from control, thrombin-and TM-treated platelets, the latter prepared in the absence of external calcium. The major difference in protein composition was the increased content of myosin associated with the cytoskeleton from TM-treated platelets where the dominant phosphoprotein was the 20,000 dalton light chain. These results suggest that myosin phosphorylation drives the initial shape changes, and via a contractile process results in the formation of the micro filament ring and centralization of granules.
Activation of human platelets by physiological agonists such as thrombin involves several stages. The initial events are an increase in cytosolic [Ca2+] and shape change; followed by centralization of the granules, aggregation, secretion and finally clot retraction. The early shape change is accompanied by cytoskeletal reorganization seen morphologically as centralization of granules, micro filament redistribution and pseudopod extension. During this process there is a shift in the equilibrium from G-actin to F-actin (Spangenberg, 1992) and an increase in the amount of myosin associated with the cytoskeleton. The latter involves phosphorylation of the 20,000 dalton (20 kD) myosin light chain and there are correlations between phosphorylation of myosin and both shape change (Daniel et al. , 1984) and myosin association with the cytoskeleton (Fox and Philips, 1982) . The kinase thought to be primarily responsible for these effects is the Ca2+ and calmodulin (CaM)-dependent myosin light chain kinase (MLCK). In intact platelets stimulated by thrombin the centralized granules are surrounded by a mass of micro filaments. Stark et al. showed that even in platelets permeabilized with saponin this structure could still be formed
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and that phosphorylation of myosin probably was an essential part of the process (Stark et al.9 1991) . A powerful tool to investigate the role of protein phosphorylation in cell function is the application of specific cytotoxic compounds. Recently it has been shown that several toxins, including okadaic acid and calyculin-A (CL-A) isolated from marine sponges, and tautomycin (TM) isolated from Streptomyces spiroverticillatus are potent inhibitors of protein phosphatase activity. Both compounds inhibit protein phosphatases type 1 and type 2A. Obviously the level of protein phosphorylation depends on the balance of kinase and phosphatase activities. The value of these phosphatase inhibitors is that they alter this equilibrium and effectively "freeze" the protein substrates in their phosphorylated state. Initially these compounds were used to probe smooth muscle function, and cytoskeletal structure in non-muscle cells. These include: okadaic acid ), calyculin-A (Chartier et al.9 1991 Hirano et aL, 1992) microcystins (Eriksson et al. 9 1990) and tautomycin (Kurisaki et al , 1993) . For example, exposure of 3T3 fibroblasts to CL-Ainduced extensive shape change and reorganization of the cytoskeleton. Associated with these changes was an increased phosphorylation of the 20 kD myosin light chain, vi-mentin and an unidentified componentof approximately 440kD (Chartier et al., 1991; Hirano et al., 1992) .
These effects did not require the presence of external Ca2+ and occurred with EGTAin the growth medium.
In previous studies of platelets (Lerea, 1991; Karaki et al., 1989; Higashihara et al, 1992; Murata et al., 1992) it was shown that okadaic acid inhibits thrombininduced aggregation , ATP and serotonin release and an increase in cytosolic [Ca2+] . CL-Abehaves similarly (Murata et al., 1992) and also causes platelet shape change (Yano et al., 1994) , although the cytoskeletal proteins involved in CL-A induced morphologic changes were not determined. Our intent was to identify major changes in platelet morphology following treatment with phosphatase inhibitors and to compare these to patterns of protein phosphorylation and alterations in platelet function. The platelet is an interesting subject for these studies. It is knownthat the cytoskeleton is a dynamic structure and is regulated, in part, by phosphorylation.
In addition, platelets contain vimentin (Muszbek et al., 1987; Tablin and Taube, 1987) but unlike the other cells studied are anucleate and thus lack the vimentin attachment to the nuclear lamina (Georgatos and Blobel, 1987) . Both phosphatases type 1 and 2A are found in platelets (Lerea, 1991; Erdodi et al. , 1992) and it was of interest to determine if their inhibition resulted in morphological changes. For most of the studies described, the phosphatase inhibitor, TM,was used and where appropriate was compared to the effects induced by CL-A. Both TM (Mackintosh and Klumpp, 1990; Hori et al., 1991) and CL-A (Ishihara et al., 1989) are potent inhibitors of type 1 and 2Aphosphatases and are permeable to intact cells.
MATERIALS AND METHODS
Isolation of Platelets. Venous blood, collected from healthy adult donors, was added to 0.1 vol of acid citrate dextrose (85 mMtrisodium citrate, lll mMD-glucose, 71 mM citric acid [pH 6.5]) and centrifuged at 650g for 15 min. The platelet-rich plasma (PRP) obtained as supernatant was centrifuged at 2,000 g for 15 min. The platelet pellet was suspended and washed three times with 150 mMNaCl, 10mMHEPES (pH7.6), 1 mMEDTAand finally suspended in Tyrode's buffer plus EGTA, i.e. 140mMNaCl, 5 mMHEPES, 2mM KC1, 1 mMMgCl2, 12mM NaHCO3, 5.5 mMglucose, 1 mM EGTA, 0.36mM sodium phosphate (pH7.4). All of the above operations were carried out at roomtemperature. Platelets were treated with either TM, CL-A or thrombin (Sigma) in the above Tyrode's buffer plus EGTA. 32P-Labeling. Platelets were suspendedat a concentration of approximately 8 x 108/ml in Tyrode's buffer plus EGTA and incubated with [32P] orthophosphate (0.2 mCi/ml) for 2 hr at 37°C. As required, varying exposures to TM(final concentration 10 fxM) or CL-A (final concentration, 0. 1 fiM) were carried out at the end of the incubation period. Reactions were stopped by addition of 10 vols. of Tyrode's buffer plus EGTAat 0°C followed by centrifugation at 1000g for 15 min. This washing procedure was repeated twice. The final platelet pellet was lysed in 10mM PIPES (pH 6.8), 100mM NaCl, 300mM sucrose, 3 mMMgCl2, 0.5% Triton X-100, 1 mMEGTA, 0.5 mMdiisopropyl fluorophosphate and 25 fig /ml leupeptin. Lysed samples were subjected to SDS-PAGE and autoradiography using XAR film (Kodak). Ca2+ Concentrations.
Cytosolic Ca2+ was measured using fura-2 by the procedure of Martinez-Zaguilan et al. (MartinezZaguilan et al. , 1991) . Platelets in Tyrode's buffer plus EDTA were loaded with 3fiM fura-2/AM for 30min at 37°C, washed and resuspended in Tyrode's plus EGTA. After the addition of TM, CL-A or thrombin the fluorescence of fura-2 was monitored for up to 15 min at 37°C using the ratio method.
Electron Microscopy. Ultrastructural examinations were carried out as described previously (Hirano et al. , 1992) . After treatment with TM,CL-Aor thrombin the samples were immediately fixed with several volumes of 2.5% glutaraldehyde in 0. 1 Msodium cacodylate buffer (pH 7.3) for approximately 10 min, then resuspended in fresh fixative. Samples were en bloc stained with tannic acid, post-fixed with osmium and en bloc stained with uranyl acetate then dehydrated with ethanol. Pellets were embeddedin Spurr's resin and thin sections stained with lead citrate and uranyl acetate. Immunoelectron Microscopy. Immunolocalization of myosin on thin sections was done on samples embeddedin LR White resin (Polysciences Inc.). Samples were fixed with 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3) for 10 min, dehydrated using a graded series of ethanol to 85%, incubated with 85% ethanol: LR White (1 : 1) and 3 changes of pure LR White then embedded in LR White polymerized at 60°C for 18 hr. Thin sections were blocked with 0.5% albumin, 0.005% Tween 20 in PBS for 10min, then incubated with the IgM monoclonal antibody to myosin at 4°C overnight or albumin alone as control. The sections were rinsed 3 times with phosphate-buffered saline (PBS) and incubated for 1 hr at room temperature with goat anti mouse IgM (Polysciences, Inc.) conjugated to 5 nm gold diluted 1 : 20 with PBS. Sections were rinsed with PBSthen water and stained for 4 min with uranyl acetate. Omission of primary antibody resulted in less than 2 gold beads per platelet profile. Fluorescence Labeling. Rhodamine phalloidin (Molecular Probes, Inc.) was used for detection of F-actin. Staining procedures were as described previously (Barak et al., 1980) . In brief, the platelets or PRP were fixed in 3%paraformalde-hyde in PBS (pH 7.4), washed with PBS, treated with 0.2% Triton X-100 in PBS for 5min, washed with PBS and incubated with 10 units/ml rhodamine phalloidin for 20 min. After washing twice with PBS, samples were mountedon slides. For immunostaining, platelets or PRP were fixed with 100% methanol at -20°C, washed with PBS, and incubated with blocking buffer (5% non-immune goat serum in PBS) for using the conditions of Laemmli (Laemmli, 1970) . For proteins of mass <200 kD a gradient gel of7.5 to 20% polyacrylamide (weight ratio of acrylamide: NjN^methylene-bis-acrylamide of 30: 0.8) was used. For larger proteins a 7.5% polyacrylamide gel (weight ratio of acrylamide: NjN^methylene-bisacrylamide of 30: 0.15) was used (Vincent et ai, 1991) . For Fig. 2 . Fluorescence micrographs of non-treated and TM-treated platelets. Platelets were treated as in Fig. 1 . A, non-treated platelets stained for F-actin with rhodamine phalloidin. B, treated platelets stained for F-actin. C, non-treated platelets stained for myosin with mAbto gizzard myosin and a rhodamine-conjugated anti-mouse IgM. D, treated platelets stained for myosin. E, non-treated platelets stained for tubulin with a mAband a rhodamine-conjugated anti-rat IgG. F, treated platelets stained for tubulin. Bar, 4 fim. high molecular weight standards cross linked myosin heavy chains were used (Hu et al. , 1988) in addition to commercially available preparations. The procedure of Carothers Carraway et al. (Carothers Carraway et al., 1991) was used for lectinbinding blots. Immunoblotting was carried out using the procedure of Towbin et al. (Towbin et al. , 1979) with 5% non-fat dried milk for blocking and \% non-fat dried milk as a carrier protein.
For detection of primary antibodies on Western blots, peroxidase-coupled secondary antibodies were used with either the colorimetric procedure or enhanced chemiluminescence (ECL; Amersham). For two-dimensional polyacrylamide gel electrophoresis over a pH range of 4 to 6 the procedure of Barany et al. (Barany et al., 1983) was used. Protein concentrations were estimated by the BCAprotein assay reagent (Pierce). Release of [14C] serotonin was measured as described previously (Packham et al., 1977) . Materials. Tautomycin was isolated as described (Cheng et al., 1987) and was generously donated by Dr. K. Isono (Riken, Japan). CL-A was isolated from sea sponges (Kato et al., 1986) and was a gift from Dr. N. Fusetani (Univ. of Tokyo, Japan). Preparation of myosin, vimentin, monoclonal antibodies (mAb) to myosin and generation of polyclonal antibodies (pAb) was as outlined by Chartier et al. (Chartier et al., 1991) The antibodies used were: the IgM mAbto myosin (Ito et al. , 1989) , (C5C, cross-reacts with the sub fragment 2 region of smooth muscle and non-muscle myosins); rat IgG anti-tubulin mAbpurchased from Serotec; rabbit anti-bovine cardiac a-actinin pAb, kindly provided by Dr. D.E. Goll (Univ. of Arizona);
anti-vinculin mAb (IgGl), purchased from Boehringer MannheimBiochemica; rabbit anti-gizzard talin pAb, kindly provided by Dr. M. Muguruma (Kyushu University, Japan); rabbit anti-20 kD gizzard myosin light chain pAb; rabbit anti-gizzard caldesmon pAb ; rabbit anti-gizzard MLCKpAb; rabbit anti-fibroblast vimentin pAb; and rabbit anti-bovine brain MAP1 C (recognizing cytoplasmic dynein), kindly provided by Dr. T. Yoshida (Mie University, Japan). For fluorescence localization rhodamine-labeled second antibodies were used (anti-rabbit IgG and anti-mouse IgM from Chemicon International and anti-rat IgG from Sigma).
RESULTS
Morphological changes. Platelets in Tyrode's buffer plus EGTAwere treated with TM (10 fiM) or CL-A (0. 1 /jM) and examined by transmission electron microscopy (TEM) after 5, 10, 15 and 30min. Over this time range the observed morphological changes were constant and thus a fixed time of 15 min was used in further experiments. Marked changes were observed and these were the same for TMand CL-A. The micrographs shown in Fig. 1 granules were centralized (Fig. IB) into the granulomere. Surrounding the granulomere was a layer of densely staining filaments of 6 to 7 nm diameter, i.e. actin filaments. These constitute the contractile ring, shown by the arrow in Fig. 1C . When microtubules were observed these were not colocalized with actin but were found toward the cell periphery and in pseudopods (Fig. ID) . Granule release did not occur as a result of exposure of TMor CL-Aas evident from the micrographs and as determined by measurements of 14C-serotonin release (data not shown). The morphological changes induced by TMalso were monitored by fluorescence microscopy. In control nontreated platelets the distribution of F-actin, probed by rhodamine phalloidin, appeared irregular and local areas of F-actin concentration were found in several regions of the cell. After exposure to 10 fiM TMthe F-actin distribution became more compact and assumed a ball-like structure (Fig. 2B ). These observations are consistent with those made by TEMin which the F-actin formed a centralized contractile ring. Immunofluorescence localization of myosin also is shown in Fig. 2 . In the resting platelets the myosin distribution generally was diffuse (Fig. 2C ). After treatment with TMthe myosin pattern was altered and myosin appeared in the area surrounding the granulomere (Fig. 2D) . This staining pattern, however, wasnot as compact as that observed for F-actin. In the non-treated platelets tubulin assumed a peripheral location (Fig. 2E ) and this became more diffuse following exposure to TM (Fig. 2F) . Regions of tubulin concentration were found in the pseudopodia.
The distribution of myosin was investigated further using immuno-gold localization. In the control, nonstimulated platelet the gold particles were distributed throughout the cell, although someconcentration was evident at the edges as shown by the arrows in Fig. 3A .
After treatment with TM, myosin localization remained diffuse but appeared to be excluded from the granulomere (Fig. 3B) . It is clear, however, that myosin was not confined to the contractile ring.
Cytosolic Ca2+. The platelets used in most of these studies were suspended in Tyrode's buffer plus EGTA. The rationale for this approach was that Ca2+ influx from the external mediumwouldbe eliminated as a contributory factor underlying the observed effects. However, this approach could not rule out the possibility of Ca2+ release from internal sources, on exposure to TM. To assess this possibility cytosolic Ca2+ concentrations were estimated using the fura-2 technique. As shown in EGTAwere observed by Hashimoto et aL (Hashimoto et al. 9 1992) . If the platelets were exposed for approximately 3 min to 1 mMexternal Ca2+ (in the presence of fibrinogen, 50 /ig/ml) after loading with fura-2, and then challenged with thrombin the cytosolic Ca2+ level approached 1 ftM. Thus the suspension of the platelets in EGTAdecreased the response to thrombin. Fig. 4B indicates that the addition of TM(to 10 ftM) did not alter the internal Ca2+ concentration for an exposure period over 10 min. Similarly, CL-A at 0.1 ftM did not increase cytosolic Ca2+. Thus it is concluded from these results that the morphological changes induced by TM, or CL-A, are not related to Ca2+ transients.
Protein phosphorylation. It is assumed that the changes observed on exposure to TMreflect increased levels of protein phosphorylation. To document that the overall extent of phosphorylation did indeed increase, the experiment illustrated in Fig. 5 was carried out. Platelets were equilibrated with 32P-phosphate, suspended in Tyrode's buffer plus EGTAand treated with 10 ftM TM.Samples were withdrawn at different times and subjected to SDS-PAGEand autoradiography. As shown by the autoradiograms the overall level of phosphorylation increased over the time period investigated. The increase in phosphorylation was relatively fast and even after 2 min a markedeffect wasobserved. Clearly manyproteins were phosphorylated, but a few components were more prominent. These included a component of molecular weight approximately 70 kD and proteins in positions corresponding to talin (the presence of talin at this position was established by Western blots) and the 20 kD myosin light chain. Increased phosphorylation also was apparent for a wide range of components, including proteins in the 50 and 90 kD range. To resolve some of the phosphorylated components more clearly the 15 min sample was analyzed by 2D electrophoresis and autoradiography. Several phosphorylated proteins were detected (Fig. 6) . A major change following treatment with TMwas the increased phosphor- antibody) is indicated ( Fig. 6A and B) . Vimentin was not a major componentof the platelet homogenateand was not identified by autoradiography. The identities of the heavily phosphorylated proteins (Fig. 6D) , in the Mr range of 60 to 70kD, are not known. It should be noted that this 2D pattern covers only those proteins focusing between pHs of4 and 6 since this is the range suitable for most cytoskeletal proteins.
The well-known substrate of protein kinase C, i.e. p47 or pleckstrin, would probably not be resolved since its pi ranges from 6.1 to 6.8 (Imaoka et al., 1983) . In addition, the isoforms of the 50 kD protein (Lerea, 1991) would not be separated, but 2 spots in the 50 kD range were detected at the alkaline edge of the gel.
Cytoskeleton. One objective of this study was to investigate effects of phosphorylation on cytoskeletal structure and composition. Cytoskeletons therefore were prepared from control and TM-treated platelets.
Also, the cytoskeleton from platelets activated by thrombin were prepared. Since the thrombin-induced effects are well documented this acted as an internal control. Usually thrombin activation is carried out in the presence of external Ca2+. In our case, however, the platelets were depleted of Ca2+ and thus the extent of thrombin activation was not maximal (see Fig. 4A ). The protein profiles of cytoskeletons from control, thrombin-and TM-treated platelets are shown in Fig. 7 . A number of proteins were identified using antibodies and some of the Western blots are also shown in Fig. 7 . The cytoskeleton of control platelets contained predominantly actin and associated proteins, i.e. actin-binding protein (ABP), a-actinin and caldesmon. There was some myosin associated with the control cytoskeleton but this was not a major component. For the cytoskeleton from platelets activated by thrombin (in the absence of Ca2+) there was a slight increase in the amount of ABP, caldesmon, and unidentified components of high molecular weight. Activation by thrombin in the presence of external Ca2+ resulted in an increased association of myosinwith the cytoskeleton (data not shown).
The cytoskeleton from TM-treated platelets was different from either the control or thrombin-activated samples. The major distinction was in the increased content of myosin. The proportion of actin was considerably reduced and this mayreflect the apparent losses of ABP and a-actinin. There was no preferential localization of glycoproteins (GP) Ib, lib or Ilia with the cytoskeleton from TM-treated platelets. Vimentin was occasionally detected but was not a major componentof any of the cytoskeletal preparations. The autoradiograms (Fig. 7) indicated that TM-treatment increased the extent of 20 kD light chain phosphorylation and longer exposures indicated a slight phosphorylation of the myosin heavy chain. Phosphorylation of high molecular weight components occurred in each preparation and were not unique to thrombin or TMtreatment. The level of light chain phosphorylation in control, resting platelets was variable. It was consistently less than in either thrombin-activated or TM-treated platelets but was often detected.
DISCUSSION
The above data show that the protein phosphatase inhibitors TMand calyculin-A induce marked changes in the cytoskeleton of humanplatelets. These changes are accompanied by an overall increase in the level of protein phosphorylation. Many proteins are phosphorylated following treatment with TMand it is reasonable to expect that some of these are involved in the observed morphological changes. For example, it is likely that some membraneproteins are phosphorylated and these maybe involved in the attachment of the cytoskeleton to the membrane. However, in the isolated cyto-skeleton the dominant protein to show enhanced phosphorylation was myosin and therefore was a focus of this study.
An interesting point is that these changes occurred in the absence of cytosolic Ca2+ transients. Thus TM is similar to okadaic acid Higashihara et al., 1992; Murata et al. , 1992) and CL-A (Murata et al., 1992; Yano et al., 1994) and does not increase the intracellular Ca2+ concentration in platelets. The increased phosphorylation that is observed must therefore occur at the Ca2+ concentration of the resting platelet. An obvious question is which kinase(s) is responsible for the enhanced level of phosphorylation, specifically myosin at low internal Ca2+ concentrations. Although MLCKis CaM-dependent it is possible that relatively low levels of activation are sufficient to account for this phosphorylation. Three light chain phosphorylation sites are indicated. Twoof these could be accounted for by MLCK,since platelet myosin, like smooth muscle myosin, can be diphosphorylated by MLCK (Itoh et al, 1992) . The third site suggests that a second kinase is involved, possibly protein kinase C (Tanaka et al, 1987; Ikebe and Reardon, 1990; Kawamoto et al, 1989) . This is speculative since there is no evidence to indicate that phosphatase inhibitors activate, or unmask, protein kinase C and in fact, Higashihara et al. (Higashihara et al, 1992) showed that okadaic acid did not induce phosphorylation of p47, a known target for protein kinase C. The relatively low levels of myosin heavy chain phosphorylation caused by TM, compared to substantial phosphorylation induced by phorbol esters (Kawamoto et al , 1989) , also argues against a major participation by protein kinase C. Thus the possibility that an unidentified kinase is involved in the phosphorylation of platelet myosin should be considered. An alternative explanation for the 4 components is that they represent differing phosphorylation states of two major 20 kD light chain isoforms, as suggested by Kawamotoet al.. (Kawamotoet al, 1989) . By Western blots only one major 20 kD light chain isoform was indicated in our studies and therefore we feel that the presence of 3 phosphorylation sites per light chain is a more likely explanation. Onemechanismto achieve phosphorylation of myosin at low internal [Ca2+] (see Hallam et al, 1985) would be to control the Ca2+ sensitivity of phosphorylation by regulation of phosphatase activity. If MLCKactivity is constant for a given Ca2+ concentration, then varying degrees of myosin phosphorylation would be obtained by varying phosphatase activity. Following
TMtreatment phosphatase activity is eliminated and myosin phosphorylation therefore would occur at the lower ranges of Ca2+ concentration. It should also be pointed out that the relatively high concentration of
CaMin platelet, at least 260 fiM according to White et al. (White et al.9 1981) , would favor phosphorylation (or any other CaM-dependent process) at lower Ca2+ levels.
Following the activation of platelets by physiological stimuli and prior to granule release, the platelet undergoes several morphological changes. These involve the centralization of granules, a redistribution of cytoskeletal elements and pseudopod extension. Normally these occur via an increase in cytosolic Ca2+and the activation of subsequent pathways. The same morphological changes occur as a result of phosphatase inhibition and it is our contention that the effects produced by TMor CL-A mimic the initial phases of platelet activation. It is established that myosin light chain phosphorylation via MLCK promotes a contractile response in smooth muscle and non-muscle cells (Hartshorne, 1987) and it is proposed that this mechanismunderlies the observed morphological changes. Thus the formation of the central actin ring, surrounding the granulomere is considered to be the end result of a contractile process initiated by myosin phosphorylation. Also the enhanced association of myosin with the cytoskeleton of the TMtreated platelets is consistent with this proposal. In somerespects these changes are similar to those seen with 3T3 fibroblasts treated with CL-A (Hirano et al. , 1992) , but there are important differences. With both platelets and fibroblasts there is a reorganization of micro filaments. However, in the latter a dense actin ball is formed that contains most, if not all, of the actin and myosin in the cell. In contrast, in platelets the aggregation of actin filaments forms a less compact structure, resembling the native contractile ring, that contains only part of the cell's myosin content. Another important difference is the contribution of intermediate filaments to the overall change. Intermediate filaments are not obvious in platelets. Since vimentin is found in both the soluble fraction and the cytoskeleton, following TM treatment, there appears to be no preferential localization. In fibroblasts, however, the intermediate filaments form cables that attach the ball-like structure to the periphery of the nucleus (Hirano et al. , 1992) . This tethering of the two organelles is a dominant feature of the morphology. Thus it is proposed that the morphological changes found on exposure of platelets to TM, or CL-A, follow the normal sequence of changes occuring on platelet activation. They do not represent a "generic response" that might be seen with many nucleated cells. Despite high levels of myosin phosphorylation and the formation of the contractile ring the granules remain intact. Thus it is likely that although myosin phosphorylation is adequate to account for shape change, in agreement with Daniel et al. , (1984) , it is not sufficient to promote secretion and a second process is required to initiate granule release. It has been suggested that this involves protein kinase C (Kaibuchi et al., 1983; Rink et al, 1983; Siess, 1989) .
Other investigators have demonstrated that okadaic acid and/or CL-A increase the overall level of protein phosphorylation in platelets and block granule release (Lerea, 1991; Karaki et al, 1989; Higashihara et al, 1992; Murata et al , 1992) . In total homogenates several proteins showed marked increases in phosphorylation (Lerea, 1991; Higashihara et al, 1992; Murata et al, 1992) . A commonfactor of these reports is the phosphorylation of a protein about 50 kD and it has been suggested that this protein(s) is associated with the inhibition of platelet function (Murata et al, 1992) possibly via inhibition of phosphatidylinositol metabolism (Lerea, 1992 ). An interesting suggestion (Lerea, 1992) is that phosphorylation of the 50 kD protein is due to a cdc2-related kinase. Whether this kinase phosphorylates other platelet proteins, e.g. myosin, remains to be determined. In the above study we did not focus on the 50 kD protein, because it clearly is not a major component of the cytoskeleton and therefore maynot be directly involved in modification of cytoskeletal structure. The data suggests that changes of morphologyand cytoskeletal organization are caused by myosin phosphorylation. Myosin light chain is the only cytoskeletal protein which is heavily phosphorylated with treatment of these phosphatase inhibitors indicating its regulatory role in this process. Another report (Yano et al, 1994) shows that CL-Aand okadaic acid cause shape change and microparticle shedding from the membranein a calcium independent reaction, associated with protein phosphorylation, although phosphorylated protein were not identified. Inhibition by TMand CL-Aof events subsequent to shape change and cytoskeletal reorganization, such as aggregation and granule release, may be due to inhibition of phosphoinositide hydrolysis (Walker and Watson, 1992) .
Our results have shown that treatment of platelets with the phosphatase inhibitors TMand CL-A, in the absence of physiological agonists, induces changes in protein phosphorylation and cytoskeletal structure, in contrast to an earlier report (Murata et al, 1992) . It is suggested that the pivotal event is phosphorylation of the 20 kD myosin light chain and that this initiates a contractile process to drive the micro filaments towards the center of the cell surrounding the mass of granules. This extensive cytoskeletal reorganization due to phosphatase inhibitor treatment occurs without an increase in cytosolic [Ca2+], phosphoinositide metabolism (Walker and Watson, 1992; Murphy and Westwick, 1994) , or activation of protein kinase C (the platelet protein kinase C substrate pleckstrin is not phosphorylated by treament with okadaic acid, Higashihara et al, 1992 
